Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration

Part of paid clinical trials in Beverly Hills, California.

Sponsor
Eyconis INC.
Study ID
NCT07587515
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Neovascular (Wet) Age-Related Macular Degeneration

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • EYC-0305 — BIOLOGICAL
    Extended-delivery anti-VEGF

Study Details

This Phase 1b/2a study will primarily investigate the safety and tolerability of EYC-0305 delivered by intravitreal (IVT) injection every 24 weeks in patients with neovascular (wet) age-related macular degeneration (AMD). The pharmacokinetics (PK) and immunogenicity of EYC-0305, and the effect on disease activity and vision will also be evaluated.

Key Dates

Start date
May 19, 2026
Status verified
May 2026
Primary completion
May 31, 2028
Completion
May 31, 2028

Study Design

Enrollment
30 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: EYC-0305 Dose Level 1
  • Experimental: EYC-0305 Dose Level 2
  • Experimental: EYC-0305 Dose Level 3
  • Experimental: EYC-0305 Dose Level 4

Primary Outcome Measure

Incidence and severity of ocular treatment-emergent adverse events (TEAEs) [ Time Frame: Week 72 ]

Central Contacts

Locations (5)

FacilityCityStateZIPSite coordinators
Beverly Hills, CABeverly HillsCalifornia90211-
Erie, PAEriePennsylvania16505-
Bellaire, TXBellaireTexas77401-
McAllen, TXMcAllenTexas78503-
The Woodlands, TXThe WoodlandsTexas77384-

Find similar trials in Beverly Hills, CA

By research site
Beverly Hills, CA· Beverly Hills, CAErie, PA· Erie, PABellaire, TX· Bellaire, TXMcAllen, TX· McAllen, TXThe Woodlands, TX· The Woodlands, TX

Related Studies